ArticleEndocrine2025
Risk factors and outcomes of Graves' orbitopathy after radioactive iodine therapy.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Korean Clinical Practice Framework for Thyroid Eye Disease: Integrating International Recommendations with Survey-Informed Consensus.Endocrinology and metabolism (Seoul, Korea) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeGraves' orbitopathy (GO) is a common extrathyroidal manifestation of Graves' disease (GD) and can be triggered by radioactive iodine (RAI) treatment. However, the incidence or factors influencing GO development after RAI remain unclear. We aimed to investigate the incidence, risk factors, and clinical outcomes of GO following RAI treatment in GD patients.
methodsA retrospective cohort study using data from Korea's National Health Information System (2008-2020) included GD patients treated with RAI from 2008-2018, followed until 2020. GO was identified via diagnostic codes, and risk factors were assessed using Cox proportional hazards models. Clinical outcomes were compared between patients with GO who did and did not undergo RAI.
resultsAmong 12,819 GD patients treated with RAI, 453 (3.5%) developed GO, compared to 4007 (0.3%) of 1,529,386 GD patients without RAI. The median time to GO onset post-RAI was 18.7 months. Younger age, shorter time from GD diagnosis to RAI, and smoking were significant risk factors, while post-RAI levothyroxine use reduced risk. Patients with GO after RAI required more intensive treatments, such as intravenous steroids and orbital radiotherapy, compared to those with GO not receiving RAI.
conclusionGO risk after RAI treatment was higher in younger patients, smokers, and those receiving earlier RAI. Levothyroxine treatment appeared protective. These findings emphasize the importance of patient selection, smoking cessation, timely hormone replacement, and close monitoring to mitigate GO risk and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.